Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

Cell Cycle

Volumn 14, Issue 11, 2015, Pages 1730-1737

  Schwaederle, Maria ^a   Daniels, Gregory A ^a   Piccioni, David E ^a   Kesari, Santosh ^a   Fanta, Paul T ^a   Schwab, Richard B ^a   Shimabukuro, Kelly A ^a   Parker, Barbara A ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

APC; Cancer; CDKN2A; Next generation sequencing; Patient s outcome; PTEN; TP53; Tumor suppressor

Indexed keywords

APC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; APC PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASMS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; REGRESSION ANALYSIS; TIME FACTOR; TRENDS; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; FEMALE; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PRECISION MEDICINE; PTEN PHOSPHOHYDROLASE; REGRESSION ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84943780413     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1033596     Document Type: Article

References (42)

1. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18: 6373-83; PMID: 22966018; http://dx. doi. org/10. 1158/1078-0432. CCR-12-1627.
2. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. USing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998-2006; PMID: 24846037; http://dx. doi. org/10. 1001/jama. 2014. 3741.
3. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 2014; 5 (9): 2349-54; PMID: 24811890.
4. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, et al. Molecular tumor board: the university of California San Diego Moores Cancer experience. Oncologist 2014; 19 (6): 631-6; PMID: 24797821; http://dx. doi. org/10. 1634/theoncologist. 2013-0405.
5. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014; theoncologist: 2014-0011; PMID: 24797823.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53; PMID: 1905840; http://dx. doi. org/10. 1126/science. 1905840.
7. cbioportal [Internet]. Available from: http://www. cbio portal. org/public-portal/index. do.
8. Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell L-J, McCowan C, Bourdon J-C, Purdie CA, Jordan LB, Dewar JA, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 2010; 102: 719-26; PMID: 20104224; http://dx. doi. org/10. 1038/sj. bjc. 6605540.
9. Skaug V, Ryberg D, Arab EHKMO, Stangeland L, Myking AO, Haugen A. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6: 1031-7; PMID: 10741731.
10. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Clin Cancer Res 2000; 6: 4055-63; PMID: 11051256.
11. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012; 10: 51; PMID: 22642691; http://dx. doi. org/10. 1186/1741-7015-10-51.
12. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6: 377-87; PMID: 24440717; http://dx. doi. org/10. 1016/j. celrep. 2013. 12. 035.
13. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008; 8: 56; PMID: 19036165; http://dx. doi. org/10. 1186/1471-230X-8-56.
14. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003; 10: 203-8; PMID: 12790783; http://dx. doi. org/10. 1677/erc. 0. 0100203.
15. Tang J-M, He Q-Y, Guo R-X, Chang X-J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer Amst Neth 2006; 51: 181-91; PMID: 16324768; http://dx. doi. org/10. 1016/j. lungcan. 2005. 10. 003.
16. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007; 104: 7564-9; PMID: 17452630; http://dx. doi. org/10. 1073/pnas. 0702507104.
17. Chen M-L, Xu P-Z, Peng X, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in PtenC/¡ mice. Genes Dev 2006; 20: 1569-74; PMID: 16778075; http://dx. doi. org/10. 1101/gad. 1395006.
18. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62; PMID: 19629070; http://dx. doi. org/10. 1038/nrc2664.
19. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-92; PMID: 16453012; http://dx. doi. org/10. 1038/nrc1819.
20. Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014; 15: 65-79; PMID: 24387334; http://dx. doi. org/10. 2174/1389450114666140106100909.
21. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102: 1368-74; PMID: 17972252; http://dx. doi. org/10. 1002/jcb. 21593.
22. Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev 2014; 40: 109-17; PMID: 23583268; http://dx. doi. org/10. 1016/j. ctrv. 2013. 03. 002.
23. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen J-H, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by pten loss in Mice. Cancer Cell 2009; 15: 148-59; PMID: 19185849; http://dx. doi. org/10. 1016/j. ccr. 2008. 12. 017.
24. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27: 5477-85; PMID: 18794882; http://dx. doi. org/10. 1038/onc. 2008. 248.
25. Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stál O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69: 4192-201; PMID: 19435893; http://dx. doi. org/10. 1158/0008-5472. CAN-09-0042.
26. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, Ochi N, Tanimoto M, Kiura K. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res 2013; 319: 417-23; PMID: 23274758; http://dx. doi. org/10. 1016/j. yexcr. 2012. 12. 018.
27. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarkerdirected therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol Off J Am Soc Clin Oncol 2013; 31: e137-40; PMID: 23358976; http://dx. doi. org/10. 1200/JCO. 2012. 43. 2716.
28. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-65; PMID: 21216929; http://dx. doi. org/10. 1158/1535-7163. MCT-10-0994.
29. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30: 777-82; PMID: 22271473; http://dx. doi. org/10. 1200/JCO. 2011. 36. 1196.
30. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-66; PMID: 20664172; http://dx. doi. org/10. 1172/JCI37539.
31. Alhejaily A, Day AG, Feilotter HE, Baetz T, Lebrun DP. Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res 2014; 20: 1676-86; PMID: 24449825; http://dx. doi. org/10. 1158/1078-0432. CCR-13-2175.
32. Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, Chen M. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013; 108: 2542-8; PMID: 23703248; http://dx. doi. org/10. 1038/bjc. 2013. 251.
33. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013; 4: 705-14; PMID: 23670029.
34. Pappano WN, Zhang Q, Tucker LA, Tse C, Wang J. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer 2014; 14: 430; PMID: 24927813; http://dx. doi. org/10. 1186/1471-2407-14-430.
35. Levy N, Yonish-Rouach E, Oren M, Kimchi A. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 1993; 13: 7942-52; PMID: 8247009.
36. Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets 2014; 15: 90-102; PMID: 24200292; http://dx. doi. org/10. 2174/1389450114666131108155418.
37. Palacio-Rúa KA, Isaza-Jiménez LF, Ahumada-Rodríguez E, Muñetón-Peña CM. [Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer]. Rev Gastroenterol Mex 2014; 79(2): 79-89; PMID: 24861525; http://dx. doi. org/10. 1016/j. rgmx. 2014. 05. 001.
38. Von Hoff DD, Stephenson JJ, Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28: 4877-83; PMID: 20921468; http://dx. doi. org/10. 1200/JCO. 2009. 26. 5983.
39. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18: 6356-63; PMID: 23014530; http://dx. doi. org/10. 1158/1078-0432. CCR-12-0178.
40. Rich JT, Neely JG, Paniello RC, Voelker CCJ, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 2010; 143: 331-6; PMID: 20723767; http://dx. doi. org/10. 1016/j. otohns. 2010. 05. 007.
41. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010; 1: 274-8; PMID: 21455458; http://dx. doi. org/10. 4103/0974-7788. 76794.
42. Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression. Crit Care 2005; 9: 112-8; PMID: 15693993; http://dx. doi. org/10. 1186/cc3045.